Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

Share this

The meeting explores both the benefits and risks associated with partnerships between traditional pharma and big tech companies. A panel of experts from industry, CROs, medical charities and VCs will share some of their experiences and lessons learned on how these institutions have developed strategies to deal with this evolving landscapes.

Charnwood Molecular’s Linos Lazarides will be attending and available to discuss how we can support your drug discovery projects.